BioSpring announces €100+m investment in new synthetic nucleic acid facility

The investment, more than €100m, includes state-of-the-art cleanroom infrastructure and advanced laboratories, and is expected to create approximately 200 new jobs upon completion in 2027.

The leading manufacturer of therapeutic oligonucleotides, undertakes production on behalf of clients developing such active substances. The launch of this major facility marks a strategic response to growing global demand for oligonucleotides, and represents a targeted expansion of BioSpring’s production capabilities. It is, however, not part of the German Gene and Cell Therapy Strategy launched earlier.

According to BioSping, the new facility will meet the highest regulatory standards, including current GMP guidelines. Spanning approximately 15,000 square metres, the site will include production areas, quality control laboratories, office space, and storage capacity.

With this new facility, BioSpring aims to enhance supply chain reliability for clients worldwide, while further advancing its technological capabilities. Commissioning is scheduled for 2027. The project is aligned with the company’s long-term growth strategy and is expected to contribute to strengthening Germany’s position as a manufacturing location for RNA drugs and vaccines.

Following the purchase of the site in 2022, the company had originally anticipated an earlier construction start and had placed greater emphasis on long-term expansion plans. “In future, we will be able to produce at tonne scale,” said Dr Sylvia Wojczewski, CEO of BioSpring.